Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance.
Adolescent
Adult
Aged
Aged, 80 and over
Antiviral Agents
/ therapeutic use
Carcinoma, Hepatocellular
/ epidemiology
Female
Follow-Up Studies
Guanine
/ analogs & derivatives
Hepatitis B Surface Antigens
/ blood
Hepatitis B e Antigens
/ blood
Hepatitis B, Chronic
/ blood
Humans
Incidence
Liver Neoplasms
/ epidemiology
Male
Middle Aged
Retrospective Studies
Tenofovir
/ therapeutic use
Young Adult
Hepatitis B e antigen seroclearance
Hepatitis B s antigen seroclearance
Hepatitis B virus
Hepatocellular carcinoma
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
18 Apr 2020
18 Apr 2020
Historique:
received:
13
10
2019
accepted:
25
03
2020
entrez:
20
4
2020
pubmed:
20
4
2020
medline:
14
1
2021
Statut:
epublish
Résumé
Hepatitis B e antigen (HBeAg) seroclearance has been considered as the treatment endpoint in HBeAg-positive patients with chronic hepatitis B (CHB). Although HBeAg seroclearance has been accomplished, some aspects are yet unclear. We investigated the cumulative incidence of hepatocellular carcinoma (HCC) and evaluated hepatitis B surface antigen (HBsAg) seroclearance in patients undergoing nucleos(t) ide analogue (NA)-induced HBeAg seroclearance. In this retrospective cohort study, 203 patients with CHB were HBsAg and HBeAg seropositive before NA (entecavir or tenofovir) treatment. All patient who experienced NA -induced HBeAg seroclearance were recruited. Patients with documented HBeAg seroclearance were followed-up every 6 months. Baseline characteristics and laboratory results were recorded. The mean age at HBeAg seroclearance was 40 years (range, 20-84), and the mean follow-up duration was 5 years (range, 2-11). The cumulative incidence of HCC was 1.5 to 11.5% at 1 to 8 years after HBeAg seroclearance. Cirrhosis was the only significant factor for HCC development (hazard ratio [HR], 24.651; confidence interval [CI], 3.018 to 201.365; P = 0.003). The cumulative incidence of HBsAg seroclearance was 3.5 to 18.7% after 1 to 8 years from HBeAg seroclearance. A significant proportion of patients developed HCC after NA-induced HBeAg seroclearance. The presence of liver cirrhosis at the time of HBeAg seroclearance serves as an independent factor for HCC development. Some patients with NA-induced HBeAg seroclearance achieved HBsAg seroclearance.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatitis B e antigen (HBeAg) seroclearance has been considered as the treatment endpoint in HBeAg-positive patients with chronic hepatitis B (CHB). Although HBeAg seroclearance has been accomplished, some aspects are yet unclear. We investigated the cumulative incidence of hepatocellular carcinoma (HCC) and evaluated hepatitis B surface antigen (HBsAg) seroclearance in patients undergoing nucleos(t) ide analogue (NA)-induced HBeAg seroclearance.
METHODS
METHODS
In this retrospective cohort study, 203 patients with CHB were HBsAg and HBeAg seropositive before NA (entecavir or tenofovir) treatment. All patient who experienced NA -induced HBeAg seroclearance were recruited. Patients with documented HBeAg seroclearance were followed-up every 6 months. Baseline characteristics and laboratory results were recorded.
RESULTS
RESULTS
The mean age at HBeAg seroclearance was 40 years (range, 20-84), and the mean follow-up duration was 5 years (range, 2-11). The cumulative incidence of HCC was 1.5 to 11.5% at 1 to 8 years after HBeAg seroclearance. Cirrhosis was the only significant factor for HCC development (hazard ratio [HR], 24.651; confidence interval [CI], 3.018 to 201.365; P = 0.003). The cumulative incidence of HBsAg seroclearance was 3.5 to 18.7% after 1 to 8 years from HBeAg seroclearance.
CONCLUSIONS
CONCLUSIONS
A significant proportion of patients developed HCC after NA-induced HBeAg seroclearance. The presence of liver cirrhosis at the time of HBeAg seroclearance serves as an independent factor for HCC development. Some patients with NA-induced HBeAg seroclearance achieved HBsAg seroclearance.
Identifiants
pubmed: 32305059
doi: 10.1186/s12876-020-01236-9
pii: 10.1186/s12876-020-01236-9
pmc: PMC7166314
doi:
Substances chimiques
Antiviral Agents
0
Hepatitis B Surface Antigens
0
Hepatitis B e Antigens
0
entecavir
5968Y6H45M
Guanine
5Z93L87A1R
Tenofovir
99YXE507IL
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113Subventions
Organisme : Yonsei University College of Medicine
ID : 6-2019-0091
Références
Hepatol Int. 2016 Jan;10(1):1-98
pubmed: 26563120
Hepatology. 2018 Aug;68(2):723-750
pubmed: 29624699
Gastroenterology. 2008 Aug;135(2):459-67
pubmed: 18585385
Hepatology. 2007 May;45(5):1187-92
pubmed: 17465003
Gastroenterology. 2002 Oct;123(4):1084-9
pubmed: 12360470
JAMA Oncol. 2019 Jan 1;5(1):30-36
pubmed: 30267080
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
J Hepatol. 2017 Oct 6;:
pubmed: 28989093
Clin Mol Hepatol. 2019 Jun;25(2):172-180
pubmed: 30754963
Hepatology. 2018 Aug;68(2):462-472
pubmed: 29534307
Gastroenterology. 2019 Feb;156(3):635-646.e9
pubmed: 30342034
Clin Mol Hepatol. 2019 Jun;25(2):93-159
pubmed: 31185710
Clin Mol Hepatol. 2017 Sep;23(3):205-211
pubmed: 28942624
J Clin Gastroenterol. 2016 Apr;50(4):286-94
pubmed: 26840752
Hepatology. 2010 Feb;51(2):415-21
pubmed: 19902424
Clin Liver Dis (Hoboken). 2018 Aug 22;12(1):33-34
pubmed: 30988907
J Hepatol. 2017 Nov;67(5):902-908
pubmed: 28652084
Gut. 2014 Aug;63(8):1325-32
pubmed: 24162593
Gastroenterology. 2010 Aug;139(2):474-82
pubmed: 20434450
J Korean Med Sci. 2005 Oct;20(5):816-20
pubmed: 16224156